0.22%
6.74%
-8.02%
73.08%
333.02%
977.46%
650.00%
AI Spotlight on KURN
Company Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally.It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio.The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems.
Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion.The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery.It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology.
The company is headquartered in Schlieren, Switzerland.
Market Data
| Last Price | 22.95 |
| Change Percentage | 0.22% |
| Open | 22.85 |
| Previous Close | 22.9 |
| Market Cap ( Millions) | 869 |
| Volume | 72866 |
| Year High | 32 |
| Year Low | 4.61 |
| M A 50 | 21.83 |
| M A 200 | 16.66 |
Financial Ratios
| FCF Yield | -0.38% |
| Dividend Yield | 0.00% |
| ROE | -15.20% |
| Debt / Equity | 9.25% |
| Net Debt / EBIDTA | 609.87% |
| Price To Book | 14.15 |
| Price Earnings Ratio | -95.82 |
| Price To FCF | -266.14 |
| Price To sales | 16.53 |
| EV / EBITDA | -602.23 |
News
- Jan -07 - Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
- Jan -07 - Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
- Nov -19 - Kuros Biosciences Expands into Extremities Markets
- Oct -10 - Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024
- Aug -08 - Kuros Biosciences Reports First Half of 2024 Results
- Jun -25 - Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
- Apr -24 - Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
- Apr -17 - Annual General Meeting of Kuros Biosciences Approves All Resolutions
- Mar -13 - Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
- Mar -08 - Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
- Feb -01 - Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
- Jan -31 - Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
- Jan -31 - Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
- Jan -04 - Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
- Dec -27 - Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
- Nov -28 - Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
- Oct -12 - Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management
- Aug -09 - Kuros Biosciences Reports Results for First Half 2023
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medical Devices
Expected Growth : 8.5 %
What the company do ?
Kuros Biosciences AG develops and commercializes orthobiologics and surgical solutions for surgeons, hospitals, and patients, focusing on bone graft substitutes and spinal fusion.
Why we expect these perspectives ?
Kuros Biosciences AG's 8.5% growth in Medical Devices is driven by increasing demand for orthobiologics and spinal fusion products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on innovative products, such as its proprietary fibrin-PTH technology, and growing adoption of minimally invasive surgeries are contributing to its growth momentum.
Kuros Biosciences Ag Products
| Product Range | What is it ? |
|---|---|
| CHORDA | CHORDA is a novel, patented, dural sealant that helps to prevent cerebrospinal fluid (CSF) leaks following spinal surgery. |
| NEURODAC-1 | NEURODAC-1 is a novel, patented, rhNGF-based therapy for the treatment of Alzheimer's disease. |
| KT1101 | KT1101 is a novel, patented, neurotrophic factor-based therapy for the treatment of Parkinson's disease. |
| CHORDA-MITE | CHORDA-MITE is a novel, patented, dural sealant that helps to prevent cerebrospinal fluid (CSF) leaks following spinal surgery. |
Kuros Biosciences AG's Porter Forces
Threat Of Substitutes
Kuros Biosciences AG operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Kuros Biosciences AG's customers are primarily pharmaceutical and biotechnology companies, which have limited bargaining power due to the specialized nature of the company's products and services.
Bargaining Power Of Suppliers
Kuros Biosciences AG relies on a few key suppliers for raw materials and equipment, which gives them some bargaining power, but the company's specialized requirements limit the suppliers' negotiating power.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, specialized expertise, and regulatory hurdles, which limits the threat of new entrants.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, which increases the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.87% |
| Debt Cost | 3.95% |
| Equity Weight | 91.13% |
| Equity Cost | 8.43% |
| WACC | 8.04% |
| Leverage | 9.73% |
Kuros Biosciences AG : Quality Control
Kuros Biosciences AG passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MEDCL.PA | MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends … |
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| NANO.PA | Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BAVA.CO | Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MedinCell
A-Score
1-Year Total Return ->
🥈
Kuros Biosciences
A-Score
1-Year Total Return ->
🥉
Galapagos
A-Score
1-Year Total Return ->
4
Bavarian Nordic
A-Score
1-Year Total Return ->
5
MediWound
A-Score
1-Year Total Return ->
6
